Antivirals With Activity Against Mpox: A Clinically Oriented Review.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35904001.
- Also identified by DOI 10.1093/cid/ciac622 and PMC identifier 9825831.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mpox virus is an emergent human pathogen. While it is less lethal than smallpox, it can still cause significant morbidity and mortality. In this review, we explore 3 antiviral agents with activity against mpox and other orthopoxviruses: cidofovir, brincidofovir, and tecovirimat. Cidofovir, and its prodrug brincidofovir, are inhibitors of DNA replication with a broad spectrum of activity against multiple families of double-stranded DNA viruses. Tecovirimat has more specific activity against orthopoxviruses and inhibits the formation of the extracellular enveloped virus necessary for cell-to-cell transmission. For each agent, we review basic pharmacology, data from animal models, and reported experience in human patients.
Medical subject headings
- Antiviral Agents
- Organophosphonates
- Mpox, Monkeypox